After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, BCYC falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Bicycle Therapeutics Plc ADR is $994.98M. A total of 0.55 million shares were traded on the day, compared to an average of 396.21K shares.
In the most recent transaction, Hannay Michael Charles Ferguso sold 257 shares of BCYC for 22.49 per share on Apr 11 ’24. After the transaction, the CHIEF PROD & SUPPLY CHAIN OFF now owns 22,891 company shares. In a previous transaction on Apr 03 ’24, Lee Kevin sold 3,158 shares at 23.81 per share. BCYC shares that CHIEF EXECUTIVE OFFICER owns now total 387,270.
Among the insiders who sold shares, Crockett Nigel disposed of 955 shares on Apr 03 ’24 at a per-share price of $23.81. This resulted in the CHIEF BUSINESS OFFICER holding 47,761 shares of BCYC after the transaction. In another insider transaction, Milnes Alistair sold 955 shares at $23.81 per share on Apr 03 ’24. Company shares held by the CHIEF OPERATING OFFICER now total 72,241.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. In terms of 52-week highs and lows, BCYC has a high of $28.91 and a low of $12.54.
As of this writing, BCYC has an earnings estimate of $Boise Cascade, L.L.C. per share for the current quarter. EPS was calculated based on a consensus of Balchem Corporation estimates, with a high estimate of $BCCC per share and a lower estimate of $Bicycle Therapeutics plc.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. BCYC’s latest balance sheet shows that the firm has $438.68M in Cash & Short Term Investments as of fiscal 2021. There were $44.34M in debt and $36.24M in liabilities at the time. Its Book Value Per Share was $8.74, while its Total Shareholder’s Equity was $346.25M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BCYC is Buy with a score of 4.75.
